Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new magnetic nanoparticle-based test developed at the University of Malaga can accurately detect true penicillin allergies — achieving 98% sensitivity compared to just ~17% with the leading commercial test. Since up to 25% of people claim a penicillin allergy but only 1–10% actually have one, this tool could eliminate millions of incorrect diagnoses and reduce unnecessary use of less effective, more toxic antibiotics.
Researchers at the University of Malaga have developed a magnetic nanoparticle-based diagnostic platform that could dramatically improve how we identify true beta-lactam antibiotic allergies. The technology uses 30 nm nanoparticles with an iron oxide core and silica shell — essentially tiny magnets coated with molecular hooks — to capture IgE antibodies from a patient's blood sample far more effectively than conventional methods.
In a study published in Materials Today Bio, the platform was tested on blood samples from nearly 100 individuals (50 confirmed amoxicillin-allergic patients and 44 tolerant controls). The results were striking: the new test achieved 98% sensitivity for amoxicillin, compared to roughly 17% with ImmunoCAP, the most widely used commercial test. It also outperformed conventional RAST, reducing both false positives and false negatives — all without requiring risky drug provocation tests.
By the Numbers:
Why it matters: Penicillin allergy overdiagnosis pushes clinicians toward alternative antibiotics that are often less effective, more toxic, and contribute to antimicrobial resistance. This non-invasive, lab-based test could safely clear thousands of incorrect allergy labels — though larger multicenter trials are still needed before clinical rollout.
